• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Letter: association between COVID-19 and inflammatory bowel disease.信件：COVID-19 与炎症性肠病之间的关联。
Aliment Pharmacol Ther. 2022 May;55(9):1226-1227. doi: 10.1111/apt.16814.
2
SARS-CoV-2 infection in patients with inflammatory bowel disease in the second-third wave and its comparison with data of first wave of pandemic.第二至第三波疫情期间炎症性肠病患者的新型冠状病毒2感染情况及其与第一波疫情数据的比较。
Gastroenterol Hepatol. 2022 Aug-Sep;45(7):572-573. doi: 10.1016/j.gastrohep.2021.11.001. Epub 2021 Nov 11.
3
Letter: risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications-reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort study.信件：炎症性肠病药物与严重 COVID-19 结局相关的风险-来自英国 PREPARE-IBD 多中心队列研究的令人安心的见解。
Aliment Pharmacol Ther. 2021 Jun;53(11):1236-1240. doi: 10.1111/apt.16349.
4
SARS-CoV-2 Infection in the Follow-Up of a Population With Inflammatory Bowel Disease.炎症性肠病患者随访中的新型冠状病毒2型感染
Inflamm Bowel Dis. 2022 Sep 1;28(9):e126-e127. doi: 10.1093/ibd/izac005.
5
Letter to the Editor on "Treatment Adherence and Clinical Outcomes of Patients with Inflammatory Bowel Disease Patients During the SARS-CoV-2 Pandemic".致编辑的信：关于“新冠疫情期间炎症性肠病患者的治疗依从性和临床结局”
Dig Dis Sci. 2022 Jan;67(1):348-349. doi: 10.1007/s10620-021-06957-9. Epub 2021 Apr 29.
6
Commenting on the Letter (Completing the Picture in Egypt: Response to "Inflammatory Bowel Diseases in Egypt During the COVID-19 Pandemic").对该信函的评论（完善埃及的情况：对“新冠疫情期间埃及的炎症性肠病”的回应）
Inflamm Bowel Dis. 2021 Apr 15;27(5):e66. doi: 10.1093/ibd/izab009.
7
Covid-19 and Patients with IBD: Who Is at Highest Risk for Severe Complications?新冠病毒-19与炎症性肠病患者：谁发生严重并发症的风险最高？
Dig Dis Sci. 2022 Apr;67(4):1090-1091. doi: 10.1007/s10620-021-07106-y. Epub 2021 Jun 28.
8
[Chronic inflammatory bowel disease and COVID-19].[慢性炎症性肠病与2019冠状病毒病]
Tidsskr Nor Laegeforen. 2020 Apr 8;140(7). doi: 10.4045/tidsskr.20.0230. Print 2020 May 5.
9
Management of Pregnant Women with Inflammatory Bowel Disease and COVID-19-Balancing Risks of Delayed Treatment Recommencement.炎症性肠病合并新型冠状病毒肺炎孕妇的管理——权衡延迟重新开始治疗的风险
J Crohns Colitis. 2022 Jun 24;16(5):867. doi: 10.1093/ecco-jcc/jjab214.
10
Letter: Covid-19-re-initiating clinical services for chronic gastrointestinal diseases. How and when?信件：重新启动慢性胃肠道疾病的新冠疫情相关临床服务。如何以及何时启动？
Aliment Pharmacol Ther. 2020 Oct;52(8):1414-1415. doi: 10.1111/apt.16061.

引用本文的文献

1
Risk of autoimmune diseases in patients with COVID-19: A retrospective cohort study.新型冠状病毒肺炎患者患自身免疫性疾病的风险：一项回顾性队列研究。
EClinicalMedicine. 2023 Feb;56:101783. doi: 10.1016/j.eclinm.2022.101783. Epub 2023 Jan 10.
2
Letter: association between COVID-19 and inflammatory bowel disease-Authors' reply.信函：2019冠状病毒病与炎症性肠病之间的关联——作者回复
Aliment Pharmacol Ther. 2022 May;55(9):1228-1229. doi: 10.1111/apt.16900.

本文引用的文献

1
Incidence, outcomes, and impact of COVID-19 on inflammatory bowel disease: propensity matched research network analysis.新型冠状病毒肺炎对炎症性肠病的发病率、结局及影响：倾向匹配研究网络分析
Aliment Pharmacol Ther. 2022 Jan;55(2):191-200. doi: 10.1111/apt.16730. Epub 2021 Dec 14.
2
SARS-CoV-2 vaccination in IBD: more pros than cons.SARS-CoV-2 疫苗接种在 IBD 中的应用：利大于弊。
Nat Rev Gastroenterol Hepatol. 2021 Apr;18(4):211-213. doi: 10.1038/s41575-021-00420-w.
3
Systematic Review on Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: It Is Time to Take Stock.对患有 2019 年冠状病毒病的炎症性肠病患者的系统评价：是时候进行总结了。
Clin Gastroenterol Hepatol. 2020 Nov;18(12):2689-2700. doi: 10.1016/j.cgh.2020.08.003. Epub 2020 Aug 7.
4
Review article: prevention, diagnosis and management of COVID-19 in the IBD patient.综述文章：炎症性肠病患者 COVID-19 的预防、诊断和管理。
Aliment Pharmacol Ther. 2020 Jul;52(1):54-72. doi: 10.1111/apt.15779. Epub 2020 May 26.
5
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications.欧洲克罗恩病和结肠炎组织（ECCO）与欧洲胃肠内镜学会（ESGAR）炎症性肠病诊断评估指南 第1部分：初始诊断、已知炎症性肠病的监测、并发症的检测
J Crohns Colitis. 2019 Feb 1;13(2):144-164. doi: 10.1093/ecco-jcc/jjy113.
6
Environmental triggers in IBD: a review of progress and evidence.炎症性肠病的环境触发因素：研究进展与证据回顾。
Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):39-49. doi: 10.1038/nrgastro.2017.136. Epub 2017 Oct 11.

信件：COVID-19 与炎症性肠病之间的关联。

Letter: association between COVID-19 and inflammatory bowel disease.

机构信息

Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.

Center for Health Data Science, Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan.

出版信息

Aliment Pharmacol Ther. 2022 May;55(9):1226-1227. doi: 10.1111/apt.16814.

DOI:10.1111/apt.16814
PMID:35429026
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9111250/
Abstract

This article is linked to Hadi et al. papers. To view these articles, visit https://publons.com/publon/10.1111/apt.16730 https://doi.org/10.1111/apt.16900

摘要

本文与 Hadi 等人的论文相关。欲查看这些文章，请访问 https://publons.com/publon/10.1111/apt.16730 https://doi.org/10.1111/apt.16900